Jared Holz, Mizuho Securities healthcare sector strategist, joins 'The Exchange' to discuss Insmed's lung drug being greenlit ...

Devarakonda covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Scholar Rock Holding, and Incyte. According to TipRanks, Devarakonda has an average return of -2.8% and a 37.04 ...

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and ...

Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for ...

Jefferies analyst Kelly Shi maintained a Buy rating on Insmed today and set a price target of $148.00. The company’s shares closed today at $122.00. Elevate Your Investing Strat ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill brensocatib, which will be sold under the brand ...

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to a potential multibillion ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

The US Food and Drug Administration approved New Jersey, USA-based Insmed’s (Nasdaq: INSM) fibrosis bronchiectasis (NCFB), a ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...